Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06090903
Status:
RECRUITING
Last Update Posted:
2023-10-19
First Post:
2023-10-13
Brief Title:
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
Sponsor:
Jonsson Comprehensive Cancer Center
Organization:
Jonsson Comprehensive Cancer Center
Study Overview
Official Title:
Exploration Into the Association Between Decorin DCN Expression and MR Phenotypes in GBM
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial uses a type of imaging scan called magnetic resonance imaging MRI to study brain tumor biology in patients with glioblastoma that can be removed by surgery resectable Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the United States Glioblastoma is a type of malignant glioma with very poor patient prognosis There are currently only about 3 drugs approved by the Food and Drug Administration FDA for the treatment of glioblastoma one of them being administration of bevacizumab which is very expensive It is the most widely used treatment for glioblastoma with dramatic results However previous clinical trials have not demonstrated an overall survival benefit across all patient populations with glioblastoma that has returned after treatment recurrent The study aims to identify which patients who will benefit from bevacizumab therapy by observing MRI images and corresponding imaging biomarkers
Detailed Description:
PRIMARY OBJECTIVES
I Enhancing tumors with high diffusion measurements low apparent diffusion coefficient ADCL 124 um2ms will have higher DCN protein expression compared with tumors exhibiting low diffusion measurements ADCL 124 um2ms Aim 1A II Enhancing tumors with high diffusion measurements low apparent diffusion coefficient ADCL 124 um2ms will have higher deoxyribonucleic acid DNA expression compared with tumors exhibiting low diffusion measurements ADCL 124 um2ms Aim 1B III Enhancing tumors with high diffusion measurements low apparent diffusion coefficient ADCL 124 um2ms will have higher ribonucleic acid RNA expression compared with tumors exhibiting low diffusion measurements ADCL 124 um2ms Aim 1C IV Mesenchymal-Like MES-like cells will have higher frequency of incidence of tumors with high diffusion measurements ADCL 124 um2ms and higher overall DCN expression levels compared to other genotypes
SECONDARY OBJECTIVE
I DCN immunohistochemistry IHC in-situ hybridization ISH and RNA expression within the tumor will be linearly correlated with continuous values of diffusion measurements ADCL
OUTLINE
Patients undergo one MRI scan over approximately 1 hour prior to surgery
I Enhancing tumors with high diffusion measurements low apparent diffusion coefficient ADCL 124 um2ms will have higher DCN protein expression compared with tumors exhibiting low diffusion measurements ADCL 124 um2ms Aim 1A II Enhancing tumors with high diffusion measurements low apparent diffusion coefficient ADCL 124 um2ms will have higher deoxyribonucleic acid DNA expression compared with tumors exhibiting low diffusion measurements ADCL 124 um2ms Aim 1B III Enhancing tumors with high diffusion measurements low apparent diffusion coefficient ADCL 124 um2ms will have higher ribonucleic acid RNA expression compared with tumors exhibiting low diffusion measurements ADCL 124 um2ms Aim 1C IV Mesenchymal-Like MES-like cells will have higher frequency of incidence of tumors with high diffusion measurements ADCL 124 um2ms and higher overall DCN expression levels compared to other genotypes
SECONDARY OBJECTIVE
I DCN immunohistochemistry IHC in-situ hybridization ISH and RNA expression within the tumor will be linearly correlated with continuous values of diffusion measurements ADCL
OUTLINE
Patients undergo one MRI scan over approximately 1 hour prior to surgery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2022-03536 | REGISTRY | None | None |
| R01CA270027 | NIH | CTRP Clinical Trial Reporting Program | httpsreporternihgovquickSearchR01CA270027 |